Abstract
Diabetic maculopathy is a common complication of diabetes mellitus, characterised by macular oedema and frequently accompanied by lipid exudation. It is the major cause of loss of vision from diabetic retinopathy. There is some evidence to implicate serum lipids in exudative maculopathy; cross-sectional studies suggest that higher serum lipid levels are found in patients with macular exudates, and prospective studies have shown an increased risk of exudative maculopathy if baseline cholesterol is higher.
The treatment for diabetic maculopathy is laser photocoagulation of the pigment epithelium. With the advent of systemic lipid lowering therapy over the last decade, there may be potential for medical therapy also. There is some anecdotal evidence of the effect of lipid lowering agents (particularly statins) in reducing exudate, and a number of studies have shown that lipid lowering therapy may reduce macular exudates, but numbers in these trials are small. A randomised controlled trial is now required to investigate whether the use of systemic lipid lowering therapy is of benefit in patients with exudative maculopathy, even in the absence of dyslipidaemia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Henricsson M, Tyrberg M, Heijl A, Janson L . Incidence of blindness and visual impairment in diabetic patients participating in an ophthalmological control and screening programme. Acta Ophthalmol Scan 1996; 74: 533–538
Klein R, Davis MD, Moss SE, DeMets DL . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. A comparison of retinopathy in younger and older onset diabetic persons. Adv Exp Med Biol 1985; 189: 321–335
Zander E, Herfurth S, Bohl B, Heinke P, Herrmann U, Kohnert K et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol 2000; 84: 871–876
Sparrow JM, McLeod BK, Smith TD, Birch MK, Rosethal AR . The prevalence of diabetic retinopathy and maculopathy and their risk factors in the non-insulin treated diabetic patients of an English town. Eye 1993; 7: 158–163
Roberts JM, Forrester JV . Factors affecting the migration and growth of endothelial cells from microvessels of bovine retinae. Exp Eye Res 1990; 50: 165–172
Kohner EM, Patel V, Rassam SBM . Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44: 603–607
Forrester JV, Shafiee AF, Schroder S, Knott R, McIntosh L . The role of growth factors in proliferative retinopathy. Eye 1993; 7: 276–287
Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT . Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol 1992; 114: 731–736
Antcliff RJ, Marshall J . The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223–232
Murata T, Ishibashi T, Khalil A . Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Research 1995; 27: 48–52
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977–986
United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853
United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713
Esmann V, Lundbaek K, Madsen PH . Types of exudates in diabetic retinopathy. Acta Medica Scandinavica 1963; 174: 375–384
Brown GC, Ridley M, Haas D, Lucier AC, Sarin LK . Lipaemic diabetic retinopathy. Ophthalomology 1984; 91: 1490–1495
Dodson PM, Gibson JM . Long term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy. Eye 1991; 5: 699–703
Miccoli R, Odello G, Giampietro O, Marchetti P, Cristofani R, Penno G et al. Circulating lipid levels and severity of diabetic retinopathy in type 1 diabetes mellitus. Ophthalmic Res 1987; 19: 52–56
Mohan R, Mohan V, Susheela L, Ramachandran A, Viswanathan M . Increased LDL cholesterol in non-insulin dependent diabetics with maculopathy. Acta Diabetol Lat 1984; 21: 85–89
Dornan TL, Carter RD, Bron AJ, Turner RC, Mann JI . Low density lipoprotein cholesterol: an association with the severity of diabetic retinopathy. Diabetologia 1982; 22: 167–170
Guerci B, Meyer L, Sommer S, George JL, Ziegler O, Drouin P et al. Severity of diabetic retinopathy is linked to lipoprotein (a) in type 1 diabetes. Diabetes Metab 1999; 25: 412–418
Kim CH, Park HJ, Park JY, Hong SK, Yoon YH, Lee KU . High serum lipoprotein (a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy. Diabetes Care 1998; 21: 2149–2151
Haffner SM, Klein BE, Moss SE, Klein R . Lp(a) is not related to retinopathy in diabetic subjects. Eur J Ophthalmol 1995; 5: 119–123
Kremser BG, Falk M, Kieselbach GF . Influence of serum lipid fractions on the course of diabetic macular edema after photocoagulation. Ophthalmologica 1995; 209: 60–63
Ernst I, Linner E, Svanborg A . Carbohydrate-rich, fat-poor diet in diabetes. Am J Med 1965; 39: 594–600
Dowd TC, Howard-Williams J, Thursfield V, Bron AJ, Hockaday TM, Mann JI . Diabetic retinopathy: different risk factors for exudates and haemorrhages. Int Ophthalmol 1986; 9: 11–15
Chew EY, Klein ML, Ferris FL, Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol 1996; 114: 1079–1084
Klein BE, Moss SE, Klein R, Surawicz TS . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98: 1261–1265
Hall NF, Gale CR, Sydall H, Phillips DIW, Martyn CN . Risk of macular degeneration in users of statins: cross sectional study. BMJ 2001; 323: 375–376
Stefaniotou M, Kalogeropoulos C, Psilas K . Long-term visual results after laser photocoagulation for diabetic maculopathy. Ophthalmologica 1995; 209: 64–67
Davies EG, Petty RG, Kohner EM . Long term effectiveness of photocoagulation for diabetic maculopathy. Eye 1989; 3: 764–767
Anonymous. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Opthalmol 1995; 113: 1144–1155
Yang CM . Surgical treatment for severe diabetic macular edema with massive hard exudates. Retina 2000; 20: 121–125
Deckert T, Feldt Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A . Albuminuria reflects widespread vascular damage. The Steno Hypothesis. Diabetologia 1989; 32: 219–226
Myrup B, Hansen PM, Jensen T, Kofoed-Enevoldsen A, Feldt-Rasmussen B, Gram J et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345: 421–422
van der Pijl JW, van der Woude FJ, Swart W, van Es LA, Lemkes HHPJ . Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet 1997; 350: 1743–1745
Berthet P, Farine JC, Barras JP . Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999; 53: 631–636
Haas A, Trummer G, Eckhardt M, Schmut O, Uygumer I, Pfeiffer KP . Effect of calcium dobesilate on progression of diabetic retinopathy. Klin Monatsbl Augenheilkd 1995; 207: 17–21
Berman DH, Friedman EA . Partial absorption of hard exudates in patients with diabetic end stage renal disease and severe anaemia after treatment with erythropoietin. Retina 1994; 14: 1–5
Janknecht P, Schumann M, Hansen LL . Reduction of retinal exudates in diabetic retinopathy after heparin-induced extracorporeal LDL-precipitation (HELP). A case report. Eur J Ophthalmol 1996; 6: 340–342
The West of Scotland Coronary Prevention Programme Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301–1307
The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389
Rubins H, Robins SJ, Collins D, Fye C, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1998; 341: 410–418
Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF . A three year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 458–467
Cullen JF, Ireland JT, Oliver MF . A controlled trial of Atromid therapy in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1964; 84: 281–295
Freybarger H, Schifferdecker E, Schatz H . Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipaemic agent. Med Klin 1994; 89: 594–597
Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112: 385–391
Dale J, Farmer J, Jones AF, Gibson JM, Dodson PM . Diabetic ischaemic and exudative maculopathy: are their risk factors different?. Diab Med 2000; 17: 47
Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R . Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1–S29
St Vincent Study Group. Diabetes Care and Research in Europe: the St Vincent Declaration. Diab Med 1990; 7: 360
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chowdhury, T., Hopkins, D., Dodson, P. et al. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?. Eye 16, 689–693 (2002). https://doi.org/10.1038/sj.eye.6700205
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6700205
Keywords
This article is cited by
-
External limiting membrane: retinal structural barrier in diabetic macular edema
International Journal of Retina and Vitreous (2021)
-
Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy
International Journal of Retina and Vitreous (2019)
-
‘Statins in retinal disease’
Eye (2018)
-
Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy
Journal of Nanobiotechnology (2017)
-
PPARα: an emerging therapeutic target in diabetic microvascular damage
Nature Reviews Endocrinology (2010)
